A start-up from Stanford University has formed a joint venture to further develop its drug delivery technology. N1 Life has partnered with Chinese biotech company Accuredit Therapeutics to form Napoltec, a company focused on novel drug delivery systems and the transfer of drug candidates from the lab to the clinic. N1 has developed two delivery platforms. One involves a peptide that inactivates the drug and protects it from clearance until it reaches the target site, thus improving safety and efficacy. The other involves a polymer-based formulation to deliver nucleic acids for treatments such as mRNA vaccines and DNA therapeutics. “We...